Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14407MR)

This product GTTS-WQ14407MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14407MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ8800MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ9657MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ4309MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ5508MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ2717MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ283MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14991MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW